ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2026
Burden and Impact of Frailty and Comorbidity in Individuals Screened for Lung Cancer.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between daily step counts and frailty trajectory classes in lung cancer patients undergoing radiotherapy: a prospective longitudinal study.Journal of cancer survivorship : research and practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundIndividuals undergoing lung cancer screening (LCS) have a high comorbidity burden, yet the extent and impact of frailty are unknown. We sought to characterize the predicted probability of frailty and comorbidity burden among individuals undergoing LCS and compare screening results and downstream healthcare utilization in those with less versus more frailty and comorbidity.
methodsThis cohort study linked North Carolina Lung Screening Registry data with Medicare, Medicaid, and private payer insurance claims from individuals undergoing baseline LCS between 2013 and 2020. We evaluated the predicted probability of frailty using the Faurot frailty index (FFI) and comorbidity using the Charlson comorbidity score (CCS). We compared LCS imaging results by FFI and CCS and rates of downstream imaging and invasive procedures by FFI and CCS using χ2 tests.
resultsAmong 3,923 individuals screened, 82.1% had low FFI, and 55% had CCS < 2. CCS was higher among those with higher FFI (P < 0.0001). LCS results did not differ based on FFI or CCS. In individuals with a negative LCS result, downstream imaging rates per 100 persons were higher among persons with greater than low versus low FFI [22.3%, 95% confidence interval (CI), 18.8-25.8 vs. 16.1%, 95% CI, 14.7-17.6, respectively] and among those with CCS ≥ 2 versus CCS < 2 [20.2%, 95% CI, 18.2-22.3 vs. 14.8%, 95% CI, 13.1-16.5, respectively].
conclusionsIndividuals undergoing LCS have a similar frailty burden to the general older adult population. More versus less frail individuals had a higher comorbidity burden. IMPACT: Our novel finding that the majority of screened individuals had a low predicted probability of frailty provides some reassurance that few individuals with screen-detected lung cancer may be unable to undergo treatment based on frailty criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.